These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 9222283

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Expression cloning of the cDNA encoding a melanoma-associated Ag recognized by mAb HMB-45. Identification as melanocyte-specific Pmel 17 cDNA.
    Wagner SN, Wagner C, Höfler H, Atkinson MJ, Goos M.
    Lab Invest; 1995 Aug; 73(2):229-35. PubMed ID: 7637323
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Molecular characterization of the melanocyte lineage-specific antigen gp100.
    Adema GJ, de Boer AJ, Vogel AM, Loenen WA, Figdor CG.
    J Biol Chem; 1994 Aug 05; 269(31):20126-33. PubMed ID: 7519602
    [Abstract] [Full Text] [Related]

  • 7. Identification of a novel gp100/pMel17 peptide presented by HLA-A*6801 and recognized on human melanoma by cytolytic T cell clones.
    Sensi M, Pellegatta S, Vegetti C, Nicolini G, Parmiani G, Anichini A.
    Tissue Antigens; 2002 Apr 05; 59(4):273-9. PubMed ID: 12135425
    [Abstract] [Full Text] [Related]

  • 8. Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions.
    Rothberg BE, Moeder CB, Kluger H, Halaban R, Elder DE, Murphy GF, Lazar A, Prieto V, Duncan LM, Rimm DL.
    Mod Pathol; 2008 Sep 05; 21(9):1121-9. PubMed ID: 18552823
    [Abstract] [Full Text] [Related]

  • 9. Melanoma-associated antigen expression in lymphangioleiomyomatosis renders tumor cells susceptible to cytotoxic T cells.
    Klarquist J, Barfuss A, Kandala S, Reust MJ, Braun RK, Hu J, Dilling DF, McKee MD, Boissy RE, Love RB, Nishimura MI, Le Poole IC.
    Am J Pathol; 2009 Dec 05; 175(6):2463-72. PubMed ID: 19893037
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes.
    Seiter S, Monsurro V, Nielsen MB, Wang E, Provenzano M, Wunderlich JR, Rosenberg SA, Marincola FM.
    J Immunother; 2002 Dec 05; 25(3):252-63. PubMed ID: 12000867
    [Abstract] [Full Text] [Related]

  • 12. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo.
    Cormier JN, Hijazi YM, Abati A, Fetsch P, Bettinotti M, Steinberg SM, Rosenberg SA, Marincola FM.
    Int J Cancer; 1998 Feb 09; 75(4):517-24. PubMed ID: 9466650
    [Abstract] [Full Text] [Related]

  • 13. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development.
    Chen YT, Stockert E, Tsang S, Coplan KA, Old LJ.
    Proc Natl Acad Sci U S A; 1995 Aug 29; 92(18):8125-9. PubMed ID: 7667256
    [Abstract] [Full Text] [Related]

  • 14. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules.
    Ramakrishna V, Treml JF, Vitale L, Connolly JE, O'Neill T, Smith PA, Jones CL, He LZ, Goldstein J, Wallace PK, Keler T, Endres MJ.
    J Immunol; 2004 Mar 01; 172(5):2845-52. PubMed ID: 14978085
    [Abstract] [Full Text] [Related]

  • 15. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.
    Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA.
    Proc Natl Acad Sci U S A; 1994 Jul 05; 91(14):6458-62. PubMed ID: 8022805
    [Abstract] [Full Text] [Related]

  • 16. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
    Dudley ME, Ngo LT, Westwood J, Wunderlich JR, Rosenberg SA.
    Cancer J; 2000 Jul 05; 6(2):69-77. PubMed ID: 11069222
    [Abstract] [Full Text] [Related]

  • 17. MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma.
    Du J, Miller AJ, Widlund HR, Horstmann MA, Ramaswamy S, Fisher DE.
    Am J Pathol; 2003 Jul 05; 163(1):333-43. PubMed ID: 12819038
    [Abstract] [Full Text] [Related]

  • 18. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells.
    Liu G, Ying H, Zeng G, Wheeler CJ, Black KL, Yu JS.
    Cancer Res; 2004 Jul 15; 64(14):4980-6. PubMed ID: 15256472
    [Abstract] [Full Text] [Related]

  • 19. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
    Elder DE, Rodeck U, Thurin J, Cardillo F, Clark WH, Stewart R, Herlyn M.
    Cancer Res; 1989 Sep 15; 49(18):5091-6. PubMed ID: 2548711
    [Abstract] [Full Text] [Related]

  • 20. Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy.
    Cormier JN, Abati A, Fetsch P, Hijazi YM, Rosenberg SA, Marincola FM, Topalian SL.
    J Immunother; 1998 Jan 15; 21(1):27-31. PubMed ID: 9456433
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.